Patent intelligence · US
US 6384024
Bile salt conjugates
Bile salt conjugates
Patent details — US 6384024
- Jurisdiction
- US
- Status
- expired
- Grant date
- May 7, 2002
- Expiration
- May 2, 2022
- Applicant
- Galmed International Limited
- Claims
- 16
- CPC classes
- A61P, A61P1/00, A61P1/16, A61P43/00
Quick answer
US 6384024 (Bile salt conjugates) is held by Galmed International Limited. Status: expired. Granted May 7, 2002. Expires May 2, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Galmed International Limited
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P1/00, A61P1/16, A61P43/00, A61P9/10
More from Galmed International Limited
Related pharmaceutical patents in our USPTO index.
-
US 12239712
Combination therapy for the treatment of liver disease
granted -
US 11571431
Aramchol salts
granted -
US 11197870
Treatment for hepatic fibrosis
granted -
US 11166964
Treatment for modulating gut microbiota
granted -
US 10849911
Low dose compositions of Aramachol salts
granted -
US 8975246
Bile acid or bile salt fatty acid conjugates
granted -
US 8110564
Bile acid or bile salt fatty acid conjugates
granted -
US 7501403
Bile acid or bile salt fatty acid conjugates
granted
Related coverage
Frequently asked questions
What is US patent 6384024?
US 6384024 (Bile salt conjugates) is held by Galmed International Limited. Status: expired. Granted May 7, 2002. Expires May 2, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6384024?
Galmed International Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 6384024 expire?
Our index shows an expiration date of May 2, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.